CD11 B[low] macrophages and conditioned media thereof for treating cancer and/or fibrosis
09724366 · 2017-08-08
Assignee
Inventors
- Dalit Barkan (Zichron Yaakov, IL)
- Odelya Gilon (Kiryat Bialik, IL)
- Amiram Ariel (Kiryat Motzkin, IL)
- Sagie Schif-Zuck (Haifa, IL)
- Aroesti-Assi Simaan (Maale Adumim, IL)
Cpc classification
A61K35/15
HUMAN NECESSITIES
A61K45/06
HUMAN NECESSITIES
C12N2502/00
CHEMISTRY; METALLURGY
C12N2501/58
CHEMISTRY; METALLURGY
C12N5/0645
CHEMISTRY; METALLURGY
International classification
A61K35/15
HUMAN NECESSITIES
A61K45/06
HUMAN NECESSITIES
Abstract
A conditioned medium of CD11b.sup.low macrophages and methods for preparing it are provided. Pharmaceutical compositions comprising the CD11b.sup.low macrophages conditioned medium or a culture of CD11b.sup.low macrophages and their use in the treatment of cancer or fibrosis are also provided.
Claims
1. A method for treating breast cancer, comprising administering to a subject in need an effective amount of an active agent selected from the group consisting of: (i) a conditioned cell culture medium of CD11b.sup.low macrophasges; and (ii) a pharmaceutical composition comprising (i) the conditioned cell culture medium of CD11b.sup.low macrophages, and a pharmaceutically active carrier, excipient or diluent, wherein said treatment of cancer comprises preventing or delaying cancer recurrence or occurrence of metastasis or inhibiting cancer metastasis.
2. The method according to claim 1, wherein said treating cancer, preventing or delaying cancer recurrence or occurrence of metastasis, or inhibiting cancer metastasis comprises preventing or inhibiting an outbreak of dormant cancer cells.
3. The method according to claim 1, wherein said subject in need is in cancer remission.
4. The method according to any of claims 1, wherein said dministering is performed in combination with additional one or more anti-cancer agents or treatments.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
DETAILED DESCRIPTION OF THE INVENTION
(18) Recently, some of the inventors of the present application identified and characterized a novel subset of pro-resolving macrophages designated CD11b.sup.low macrophages that appear during the resolution of murine peritonitis (Schif-Zuck et al., 2011). Furthermore, they found that these macrophages display an enzyme expression signature distinct from either M1 or M2 macrophages. CD11b.sup.low macrophages can be generated in vivo or ex vivo from M2-like macrophages that are characterized by high levels of CD11b expression and termed CD11b.sup.high macrophages, following the engulfment of apoptotic leukocytes, which is a hallmark of resolution. Furthermore, these newly discovered pro-resolving CD11b.sup.low macrophages, also termed resolution-promoting macrophages or Mres, lost their phagocytic potential and were prone to migrate to lymphoid tissues.
(19) In the present invention, the inventors show for the first time that conditioned media of these recently described CD11b.sup.low macrophages can inhibit fibrosis, as manifested by inhibition of the transition of fibroblasts into myofibroblasts, including inhibiting Type I collagen (Col-I) secretion and α-SMA expression. The inventors have further surprisingly found that a conditioned medium of CD11b.sup.low macrophages has highly effective cytotoxic and cytostatic activities. Specifically, using a three-dimensional culture system that models tumor dormancy and outbreak of disseminated tumor cells it was unexpectedly found that the conditioned medium not only inhibited the proliferation of outbreaking dormant tumor cells, but also eradicated effectively even non-proliferating dormant tumor cells, which are largely resistant to currently used chemotherapeutic agents. These characteristics indicate that the conditioned medium may be useful for preventing or inhibiting metastasis and preventing the recurrence of cancer after remission.
(20) CD11b.sup.high and CD11b.sup.low macrophages are two populations of macrophages typically isolated in murine models from peritoneal exudates during the resolution phase of peritonitis. As can be seen in
(21) The level of CD11b or other markers may be determined by various methods known in the art, e.g. immunostaining and FACS analysis, or gel electrophoresis and Western blotting. The term “CD11b.sup.high macrophages”, as used herein, relates to macrophages expressing high levels of CD11b. The term “CD11b.sup.low macrophages”, as used herein, relates to macrophages that express on their surface a level of CD11b that is substantially lower than that of Cd11b.sup.high macrophages. Sometimes the term “CD11b deficient macrophages” is used to define “CD11b.sup.low macrophages” and both terms should be considered as synonyms.
(22) The term “culture macrophages” refers herein to human macrophages differentiated in culture from peripheral blood mononuclear cells (PBMC). Culture macrophages are typically obtained by incubating PBMC for 5-7 days. In some embodiments, the cells are cultured in the presence of autologous serum (e.g. 1-10%, preferably 10%), this being serum obtained from the blood of the patient to whom the culture of CD11b.sup.low macrophages or the conditioned medium thereof will be administered. In some other embodiments, the cells are cultured in a suitable medium such as RPMI 1640, supplemented with 10% human serum, 2 mM L-glutamine, 100 μg/ml streptomycin, and 100 units/ml penicillin, to which granulocyte-macrophage colony stimulating factor (GM-CSF; e.g. 10 μg/ml) or, preferably, macrophage colony stimulating factor (M-CSF; e.g. 25 μg/ml), has been added.
(23) It is shown herein that expression of CD11b on Cd11b.sup.high macrophages was about tenfold higher than its expression on CD11b.sup.low macrophages. The amount of CD11b in protein extracts of CD11b.sup.low macrophages was also significantly lower than its amount in the extracts from CD11b.sup.high macrophages (see Example 1).
(24) Thus, according to some embodiments of the invention, the mean level of expression of CD11b.sup.low macrophages is defined as being 2-100 times lower than the mean CD11b expression on CD11b.sup.high macrophages or on culture macrophages. According to some embodiments, the mean level of expression of CD11b.sup.low macrophages is 2-10 times lower than the mean CD11b expression on CD11b.sup.high macrophages or on culture macrophages. According to some embodiments, the mean level of expression of CD11b.sup.low macrophages is 11-100 times lower than the mean CD11b expression on CD11b.sup.high macrophages or on culture macrophages. According to some embodiments, the level of CD11b expression on CD11b.sup.low macrophages is undetectable. Thus, according to some embodiments, the level of CD11b expression on CD11b.sup.low macrophages may be defined as 0 (zero). All the CD11b level measurements define surface expression detected by flow cytometry.
(25) As mentioned above and explained in more detail below, CD11b.sup.low murine macrophages can be isolated from a macrophage population retrieved during the resolution phase of murine peritonitis. Additionally, CD11b expression on the surface of both CD11b.sup.high and CD11b.sup.low macrophages can be significantly reduced following their incubation with apoptotic cells (see Examples 6, 9). However, following incubation with apoptotic cells, some of the macrophages have even lower expression levels of CD11b compared to the level of expression found for CD11b.sup.low macrophages isolated from peritoneal exudates, and are termed CD11b.sup.− macrophages. Therefore the ex vivo-generated population of macrophages expressing low levels of CD11b may be comprised from both CD11b.sup.low and CD11b.sup.− macrophages.
(26) Accordingly, the definition of CD11b.sup.low macrophages also includes CD11b.sup.− macrophages that are substantially devoid of surface CD11b or have very low, barely detectable, levels of CD11b or no CD11b at all.
(27) According to some embodiments of the present invention, the population of CD11b.sup.low macrophages is comprised of a heterogeneous population of cells. Typically, at least 50% of the heterogeneous populations of cells are CD11b.sup.low macrophages. In some embodiments, more than 55%, 60%, 65%, 70%, 75% or more than 80% of the cells are CD11b.sup.low macrophages in heterogeneous populations [see
(28) In some embodiments, the population of CD11b.sup.low macrophages is comprised of a homogeneous population, meaning that it is substantially devoid of macrophages that are not CD11b.sup.low macrophages.
(29) The terms “CD11b deficient macrophages”, “resolution-promoting macrophages”, “pro-resolving macrophages”, or “Mres” are used hereinbelow interchangeably with, and have the same meaning as, “CD11b.sup.low macrophages”.
(30) The effect of treating mouse embryonic fibroblasts (MEF) with a conditioned medium from CD11b.sup.low macrophages was shown in Examples 10-14. To mimic the process of fibrosis, mouse embryonic fibroblasts (MEFs) were induced to differentiate to myofibroblasts by treating the cells with TGFβ1. As shown in Example 10, treatment with conditioned medium from Mres (CD11b.sup.low macrophages) of MEFs which were induced with TGFP, resulted in less proliferation than treatment with conditioned medium from CD11b.sup.high macrophages. Further, according to Example 11, this lack of proliferation was most likely due to growth arrest, since most of the MEFs were alive and did not stain by a TUNEL assay, which detects apoptosis. Example 12 shows that conditioned medium from CD11b.sup.low significantly inhibited the expression of α-SMA in MEF (α-SMA marks their differentiation to myofibroblasts) treated with TGFβ1 compared to the expression levels in MEF treated with TGFβ1+conditioned medium from CD11b.sup.high macrophages. According to Examples 13 and 14, conditioned medium from CD11b.sup.low macrophages significantly inhibited Col-I expression of TGFβ1-treated MEFs compared to untreated MEFs and to TGFβ1-treated MEFs that were treated with conditioned medium from CD11b.sup.high macrophages.
(31) Additionally, the effect of a conditioned medium from CD11b.sup.high macrophages on the proliferation of dormant tumor cells was shown in Examples 15 and 16 for tumor cells cultured in a modified 3D culture system constituted from growth factor reduced basement membrane (BME; a specialized ECM). This 3D BME system, described recently in Barkan et al., 2011, can model tumor dormancy and outgrowth. Supplementing the 3D BME system with Col-I was shown to induce the transition of dormant tumor cells from quiescence to proliferative growth. Example 15 shows that conditioned media from CD11b.sup.high cells induced cell death in outbreaking tumor cells during their transition from dormancy to proliferation in the 3D system, and also of dormant tumor cells. Additionally, Example 16 shows that treating dormant tumor cells co-cultured in the 3D BME system with a conditioned medium from CD11b.sup.high macrophages causes them to emerge from their dormant state, but treatment with a conditioned medium from CD11b.sup.low macrophages prevented Col-I expression by the differentiated MEFs and resulted in lower numbers of tumor cells.
(32) In one aspect of the invention, there is provided a conditioned cell culture medium of CD11b.sup.low macrophages or a biologically active fraction thereof.
(33) The term “conditioned medium” in general refers to a growth medium in which cells have been cultured/incubated for a period of time followed by harvest of such medium from the cultured cells. A conditioned medium contains metabolites, growth factors, and extracellular matrix proteins secreted into the medium by the cultured cells.
(34) In accordance with the present invention, the term “conditioned medium of CD11b.sup.low macrophages” refers to the medium harvested from the cultured macrophages after the incubation with either apoptotic cells or with a pro-resolving lipid mediator, when the CD11b.sup.low macrophages are obtained. The conditioned medium may be derived from autologous serum or from a medium suitable for culture of monocytes such as, but not limited to, Iscove's Modified Dulbecco's Medium (IMDM) and RPMI 1640, and may contain additional nutrients.
(35) In some embodiments of the invention, the conditioned medium of CD11b.sup.low macrophages is based on RPMI 1640 with 10% fetal bovine serum (FBS) or 10% human serum and supplemented with 2 mM L-glutamine, 100 μg/ml streptomycin, and 100 units/ml penicillin. It also contains soluble factors secreted by the cultured cells into the medium. The conditioned medium may be purified, e.g. by filtration or centrifugation, to provide substantially cell free preparations.
(36) In the method for preparing the conditioned medium of the invention, in a first step a population of mononuclear cells of the monocyte/macrophage lineage, preferably human monocytes, is cultured for 5-7 days, so as to induce differentiation of said mononuclear cells/monocytes to macrophages. The culture is made in autologous serum or in a medium suitable for culture of monocytes as defined above in paragraphs [0071] and [0083].
(37) In a second step of the method, the macrophages obtained in the first step, which are mainly CD11b.sup.high macrophages, are incubated with an agent that will reduce the CD11b expression of the macrophages so as to obtain a macrophage population mainly constituted of CD11b.sup.low macrophages.
(38) In some embodiments, the agent used for reduction of the CD11b expression of macrophages is apoptotic cells.
(39) As shown in Example 1 hereinafter, CD11b.sup.high and the CD11b.sup.low macrophage populations are distinct populations, as shown by the difference in protein expression profiles between these two populations, For example, CD11b.sup.low macrophages may express lower levels (typically 2-10 times lower) of COX-2 and/or MMP-9 compared to CD11b.sup.high macrophages. CD11b.sup.low macrophages may also express 12/15-LO at a level significantly higher than CD11b.sup.high macrophages. CD11b.sup.low typically express iNOS, arginase-1 or actin a significantly reduced level compared to CD11b.sup.high macrophages, or in the case of iNOS or arginase-1, possibly not at all.
(40) CD11b.sup.low macrophages may therefore be further characterized by their expression level of certain additional markers, such as an increased expression level of 12/15-LO and/or a reduced expression level of iNOS, arginase-1 or actin.
(41) Example 2 shows that CD11b.sup.low macrophages engulfed significantly more PMN on average than CD11b.sup.high macrophages and the two populations were distinguished by an engulfment threshold of seven PMN. Example 4 shows that CD11b.sup.low macrophages may be considered “satiated”, meaning that they lost their phagocytic potential upon meeting the apoptotic PMN engulfment threshold and reducing their CD11b expression.
(42) To avoid potential residual effect of the apoptotic cells (AC) in the conditioned media, it is important that most AC is engulfed by the macrophages. Example 9 shows the effect of different ratios of CD11b.sup.high macrophages to AC, on the fraction of AC that remains after engulfment. A ratio of 1:1 left only 8% AC not engulfed, while higher macrophage/AC ratios of 1:1.5, 1:2 or 1:5 left more AC not engulfed.
(43) Accordingly, in some embodiments the incubation of mononuclear cells in the presence of apoptotic cells is performed at a ratio of mononuclear cells to apoptotic cells of between 1:1 and 1:5. In some embodiments, the ratio between mononuclear cells and apoptotic cells is between 1:1 and 1:1.5. In some embodiments, the ratio between mononuclear cells and apoptotic cells is 1:1. In some embodiments incubation of mononuclear cells in the presence of apoptotic cells is performed for 16-24 hours. For example, the incubation with the apoptotic cells may take from 5 to 10, preferably 8, hours, followed by washing of the cells (e.g., with PBS), addition of fresh medium and further incubation for 10-15, preferably, 12, hours. In some embodiments the incubation of mononuclear cells in the presence of apoptotic cells is performed such that the average number of engulfed apoptotic cell per mononuclear cell is 7. In some embodiments incubation of mononuclear cells in the presence of apoptotic cells is performed in the presence of one or more anti-inflammatory agents such as, but not limited to, IL-10, TGFP, PPARX, ligand, vitamin D and its derivatives, glucocorticoid, or other pro-resolving lipid mediators.
(44) In certain embodiments the apoptotic cells are polymorphonuclear cells. In some embodiment the apoptotic cells are neutrophils. In some embodiment the apoptotic cells are lymphocytes, e.g. T cells. Such cell populations may be produced by standard procedures known in the art. Apoptosis may be induced by a variety of well-known methods including but not limited to, incubation with staurosporine (e.g. 1 μM for 4 hr) or etoposide (0.5 ρM), or exposure to UV irradiation (e.g. 5 minutes). Apoptosis may also be induced in neutrophils by prolonged incubation (e.g. for 12-24 hours) in culture media in the absence of cytokines. Any type of apoptotic cells may be used such as apoptotic Jurkat T cells after treatment with staurosporine.
(45) In some other embodiments, the agent used for reduction of the CD11b expression of macrophages is a pro-resolving lipid mediator. The pro-resolving lipid mediator may be selected from, without being limited to, a lipoxin (LX), a resolvin (Rv), a protectin (PD), a maresin (MaR), or a glucorticoid. Examples of such agents, without being limited to, are lipoxin LXB.sub.4 and 15-epi-LXA.sub.4, resolvins RvD1 and RvD2, protectin PD1, and dexamethasone.
(46) Example 7 shows that resolvins (RvD1, RvE1) and glucocorticoids (Dex) enhanced the appearance of CD11b.sup.low macrophages and RvD1 and RvE 1, but not Dex, also reduced CD11b expression on CD11b.sup.high macrophages. The secretion of IL-10, a pro-resolving cytokine generated following the ingestion of apoptotic cells, was up-regulated by each of the pro-resolving mediators, in unstimulated and LPS-stimulated macrophages.
(47) Thus, treatment with RvD1, RvE1, and Dex, promoted macrophage immune-silencing, as well as the secretion of pro-resolving cytokines from these cells. Example 8 shows that ex vivo treatment with the pro-resolving lipid mediators RvD1 or RvD2, the protectin PD1, the lipoxins LXB.sub.4 or 15-epi-LXA.sub.4, or dexamethasone (Dex), promotes macrophage switch to the CD11b.sup.low phenotype similarly to the effect of incubation with apoptotic cells. Therefore, such treatment can possibly either enhance the effect of incubating with apoptotic cells in order to enrich for CD11b.sup.low macrophages, or such treatment with pro-resolving lipid mediators may replace incubation with apoptotic cells.
(48) In the last step of the method, the conditioned medium is collected from the culture of the CD11b.sup.low macrophages and further purified by standard procedures.
(49) In a further aspect, the present invention relates to a pharmaceutical composition comprising the conditioned cell culture medium of CD11b.sup.low macrophages of the invention, or a biologically active fraction thereof, and a pharmaceutically acceptable carrier, excipient or diluent.
(50) The conditioned medium of the present invention or prepared according to the methods of the present invention or fractions thereof can be administered to individuals in need per se or in a pharmaceutical composition with suitable carriers, excipients or diluents.
(51) As used herein, the term “a biologically active fraction thereof” refers to a fraction of the conditioned cell culture medium of CD11b.sup.low macrophages obtained by fractionation of the conditioned medium and shown to retain the same biological activities as shown herein for the whole conditioned medium such as cytotoxic, anti-metastatic or anti-fibrotic activity. Conveniently, the biological activity may be determined using the three dimensional culture system that models tumor dormancy and breakout, e.g. as exemplified in the Examples section below. The fractionation of the conditioned medium may be carried out by standard procedures, e.g. organic extractions, size exclusion fractions and/or HPLC fractionation, as known in the art.
(52) The term “pharmaceutically acceptable carrier” refers to a carrier or diluent that does not cause irritation or other adverse effect to an organism and does not have an adverse effect on the biological activity and properties of the administered compound. The “excipient” refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.
(53) Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, grinding, pulverizing, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
(54) Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active agents into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
(55) Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal, or parentersl delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal or intraocular injections.
(56) Alternatively, the pharmaceutical composition may be administered in a local rather than systemic manner, for example, via injection directly into a tissue region of a patient.
(57) For injection, the active ingredients of the compositions of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants for example DMSO, or polyethylene glycol are generally known in the art.
(58) Pharmaceutical compositions suitable for use in context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a “therapeutically effective amount” means an amount of an active ingredient effective to prevent, alleviate or ameliorate symptoms of a disease or disorder or prolong the survival of the subject being treated.
(59) Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
(60) Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations or a single administration of a slow release composition, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.
(61) The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.
(62) The CD11b.sup.low macrophages or the conditioned media thereof may be re-infused (in the case of autologous treatment, or infused, in the case of an allogeneic treatment) into the patient (e.g. in a physiologic PBS solution) systemically, e.g. intravenously, by conventional clinical procedures. Patients may generally receive from about 10.sup.6 to about 10.sup.12 macrophages, depending on the condition of the patient. The macrophages administered are typically viable and may optionally be activated prior to administering to the subject (e.g. by treatment with corticosteroids, PPARγ agonists, TGFβ or vitamin D).
(63) The conditioned cell culture medium of CD11b.sup.low macrophages, a biologically active fraction thereof or a pharmaceutical composition comprising them can be used for treatment of cancer or fibrosis.
(64) The term “treating” or “treatment” as used herein includes abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical symptoms of a condition or substantially preventing the appearance of clinical symptoms of a condition, With regard to cancer, the term refers to preventing or delaying cancer recurrence or occurrence of metastasis, inhibiting tumor growth or causing death of cancer cells, especially of metastatic cancer cells. Such treatment can also lead to regression of tumor growth, i.e., to decrease in size or complete regression of the tumor, and to elimination of metastases. The terms “tumor” and “cancer” are used interchangeably herein.
(65) According to some embodiments, the treatment according to the present invention prevents the proliferation or outbreak of dormant tumor cells.
(66) The terms “dormant cells” or “dormant tumor cells” as used herein relate to either of the two states that have been described regarding tumor dormancy. Dormant tumor cells may exist in a quiescent state for many years as solitary quiescent tumor cells as demonstrated by their negative staining for the proliferation marker Ki67 and their negative staining for apoptosis. Alternatively, tumor dormancy may exist as micrometastases where cellular proliferation is balanced by apoptosis. These micrometastases remain dormant because of lack of recruitment of the vasculature needed to nourish the tumor, known as the angiogenic switch and/or involvement of the adaptive immune system such as cytotoxic CD8.sup.+ T cells.
(67) In some embodiments of the invention, the treatment of cancer comprises inhibiting cancer metastasis.
(68) The term “treating” or “treatment” as used herein with regard to fibrosis, refers to preventing the occurrence of fibrosis or inhibiting fibrosis by inhibiting the progress and/or the extent of the fibrotic process.
(69) The term “fibrosis” as used herein, relates to a process in which excess fibrous connective tissue is formed in an organ or tissue in a reparative or reactive process. In the process of fibrosis, the connective tissue deposited can obliterate the architecture and function of the underlying organ or tissue. Fibrosis can happen in response to injury (scarring) or as part of a pathological process such as, for example, in liver disease, kidney disease, pulmonary fibrosis or heart failure.
(70) In a further aspect, the present invention is directed to a culture of isolated CD11b.sup.low human macrophages or a cellular therapy preparation comprising said culture and a pharmaceutically active carrier, excipient or diluent, for use in the treatment of cancer or fibrosis.
(71) In yet a further aspect, the present invention provides a method for treating cancer comprising administering to a subject in need an effective amount of an active agent selected from : (i) a conditioned cell culture medium of CD11b.sup.low macrophages; (ii) a biologically active fraction thereof; (iii) a pharmaceutical composition comprising (i) or (ii) and a pharmaceutically active carrier, excipient or diluent; (iv) a culture of human CD11b.sup.low macrophages; or (v) a pharmaceutical composition comprising (iv) and a pharmaceutically active carrier, excipient or diluent, wherein said treatment comprises preventing or delaying cancer recurrence or occurrence of metastasis or inhibiting cancer metastasis.
(72) The types of cancer that can be treated by the method of the invention are typically cancers that relapse, meaning that the patient can be in remission, that is, free of active disease, but the cancer may become active again. As explained above, recurrence of the disease is generally due to the presence of dormant cells which may become activated. Additionally, treatment-eligible tumors are also those which metastasize.
(73) Accordingly, in some embodiments, the active agents of the invention may be used to prevent and treat recurring metastatic cancers. It is also appreciated that they can be used also for treatment of patients with an active cancer, for example, to prevent further metastases or inhibit the level of tumor spreading.
(74) In some embodiments, the cancer is selected from breast, prostate, esophageal, skin, lung, head and neck, colon or liver cancer. In some embodiments, the cancer is breast cancer.
(75) In some embodiments, the cancer is resistant to chemotherapy, immunotherapy, anti-angiogenic therapy and/or radiotherapy. In some embodiments, the cancer is resistant to chemotherapy and/or radiotherapy. In some embodiment the cancer is resistant to hormone responsive therapy. For example, the compositions and methods of the invention may be suitable for the treatment of heterogeneous hormone responsive tumors (e.g. breast or prostate tumors), which are not amenable for treatment with conventional hormone responsive therapies since the respective receptors are not expressed on substantially all the tumor cells. Advantageously, the treatments of the invention may be used for treatment of triple-negative breast cancer, i.e. breast tumors not expressing the genes for estrogen receptor (ER), progesterone receptor (PR) and Her2/neu, which are thus not amenable for treatment with hormone-responsive therapies. Often, such triple negative breast tumors are also resistant to immuno-therapies (e.g. Herceptin) or treatment with small molecules (e.g. Lapatinib.
(76) Optionally, the active agents or compositions of the invention may be administered to the subject in combination (concurrently or sequentially) with other anti-cancer agents or treatments. For example, they may be administered in combination with one or more chemotherapeutic agents such as, but not limited to, alkylating agents, e.g. Cyclophosphamide, Ifosphamide, Melphalan, Chlorambucil, BCNU, CCNU, Decarbazine, Procarbazine, Busulfan, and Thiotepa; antimetabolites, e.g. Methotraxate, 5-Fluorouracil, Cytarabine, Gemcitabine, 6-mercaptopurine, 6-thioguanine, Fludarabine, and Cladribine; anthracyclins, e.g. daunorubicin. Doxorubicin, Idarubicin, Epirubicin and Mitoxantrone; camptothecins, e.g. irinotecan and topotecan; taxanes, e.g. paclitaxel and docetaxel; and platinums, e.g. Cisplatin, carboplatin, and Oxaliplatin, as well as to immunotherapies, e.g. Herceptin and Cetuximab, hormone responsive therapies, e.g. Tamoxifen, Raloxifene, Fulvestrant, Anastrozole, Letrozole or Exemestane for breast cancer, or anti-androgens e.g. flutamide for prostate cancer, small molecules inhibiting epidermal growth factor receptor (EGFR, e.g. Lapatinib or gefitinib), anti-angiogenic therapy, e.g. Bevacizumab, sunitinib, sorafenib and pazopanib, antibodies and small molecules targeted against beta 1 integrins (e.g. ATN-161, Volociximab and JSM6427), or inhibitors, antagonists and small molecules against urokinase receptor (UPAR).
(77) Advantageously, the compositions of the invention may be used in conjunction (concurrently or sequentially) with surgery or radiotherapy. For example, the cells or cell-free preparations of the invention may be used concomitantly with, or within 1-4 days of, a surgical treatment for cancer. Dissemination of tumor cells, which are the source for the recurrence and progression to metastatic disease, may occur as a result of the surgical operation. By performing such procedures in conjunction with the compositions of the invention, cancer recurrence or metastasis may be prevented or inhibited. Thus the compositions and methods of the invention may be used to inhibit post-surgery metastatic process.
(78) Given that dissemination of tumor cells may have already occurred even at an early stage of tumor progression, the anti-cancer agents or treatments that may be administered in combination with the compositions of the invention, include, in some embodiments, neoadjuvant treatment, namely radiotherapy, chemotherapy, hormone therapy and/or immunotherapy used for shrinking the size of the tumor prior to surgical operation.
(79) In yet a further aspect, the present invention provides a method for treating fibrosis comprising administering to a subject in need an effective amount of an active agent selected from : (i) a conditioned cell culture medium of CD11b.sup.low macrophages; (ii) a biologically active fraction thereof; (iii) a pharmaceutical composition comprising (i) or (ii) and a pharmaceutically active carrier, excipient or diluent; (iv) a culture of human CD11b.sup.low macrophages; or (v) a pharmaceutical composition comprising (iv) and a pharmaceutically active carrier, excipient or diluent, wherein said treatment of fibrosis comprises preventing or inhibiting fibrosis.
(80) Examples 15 and 16 hereinafter show that development of fibrosis can be the cause of activation and proliferation of dormant tumor cells. Since the active agents of the invention can prevent the process of fibrosis, they also prevent proliferation of the dormant tumor cells. Thus, treatment of the fibrosis associated with cancer is encompassed by the present invention.
(81) Examples 10-14 show that conditioned medium of CD11b.sup.low macrophages can inhibit proliferation of fibroblasts and their differentiation into myofibroblasts induced by TGFβ, including inhibiting expression of α-SMA and deposition of Col-I, which marks the process of fibrosis. These results demonstrate for the first time that conditioned medium of CD11b.sup.low macrophages can prevent fibroblasts from differentiation into myofibroblasts and secretion of Col-I. Without being bound to any theory, the inventors believe that these results indicate that these macrophages may secrete anti-fibrotic factors that can prevent the establishment of a fibrotic microenvironment.
(82) Accordingly, in some embodiments, the fibrosis is associated with a disease or a condition selected from acute lung injury, Alzheimer's disease, chronic diabetic wounds, chronic granulomatous disease (CGD), chronic obstructive pulmonary disease (COPD), constrictive pericarditis, Dupuytren's disease, emphysema, hypertrophic burn scars, keloid, liver cirrhosis, plantar fibromatosis, retinal detachment inflammation, scleroderma, cystic fibrosis, endometrial fibrosis, idiopathic pulmonary fibrosis, myocardial fibrosis, nephrogenic fibrosis, pancreatic fibrosis, perineural fibrosis, renal interstitial fibrosis, secondary fibrosis in the gastrointestinal tract or fibrosis resulting after surgery.
(83) The following examples are presented in order to more fully illustrate some embodiments of the invention. They should, in no way be construed, however, as limiting the scope of the invention.
EXAMPLES
(84) Materials and Methods
(85) Reagents
(86) ELISA kits for mouse TNF-α, IL-1β, IL-10, TGFβ, CCL2, CCL3, and CCL5 ere obtained from R&D Systems. CFSE, staurosporine, LPS (from Escherichia coli, clone 055:B5), PKH2-PCL green fluorescence linker kit, and dexamethasone (Dex) from Sigma. Poly (I:C) and CpG-ODN from InvivoGen. RvE1 (5S,12R,18R-trihydroxy-4Z,8E,10E,14Z,16E-eico sapentaenoic acid) and RvD1 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid) were obtained from Cayman Chemicals and the synthetic Rv were matched according to the previously published biological and physical material, PD1, LXB.sub.4, or 15-epi-LXA.sub.4 were a gift from Prof. Serhan, Harvard.
(87) Isolation and Culture of Human Monocytes
(88) PBMC is obtained following informed consent from individual/patient by Ficoll density centrifugation (400 g, 30 min, without brake), and is washed three times with RPMI. Monocytes are further purified by adherence: cell pellet is resuspended in culture media (RPMI 1640, supplemented with 10% human serum, 2 mM L-glutamine, 100 μg/ml streptomycin, and 100 units/ml penicillin) and 10×10.sup.6 cells per well are transferred to 6-well plates, and incubated horizontally for 1.5 hrs at 37° C. in 5% CO.sub.2, humidified environment. Then, nonadherent lymphocytes are discarded and the plates are washed gently with fresh RPMI.
(89) The isolated monocytes are then collected and differentiated to macrophages either with 10% autologous serum or with MCSF.
(90) Murine Peritonitis
(91) Male C57BL/6 mice (6-8 wk) were injected intraperitionealy (I.P) with zymosan A (1 mg). 66 hours post zymosan A injection, the mice were euthanized by CO.sub.2, their peritoneal cavity was lavaged with 5 ml of phosphate buffered saline (PBS) and the peritoneal exudates were collected by centrifugation for further analysis and experimentation.
(92) Peritoneal exudates were collected and exudate cells were stained with FITC-conjugated rat anti-mouse Ly-6G, PE-conjugated rat anti-mouse F4/80, and PerCP-conjugated rat anti-mouse CD11b (Biolegend) and analyzed by FACSCalibur (Beckton-Dickinson). Macrophages were isolated using EasySep PE selection magnetic beads following the manufacturer's instructions (StemCell Technologies).
(93) In some experiments, the macrophages were sorted to CD11b.sup.high and CD11b.sup.low populations of >95% purity, using FACSaria (Beckton-Dickinson), and the separate populations were used for microscopic analysis and for ex vivo stimulation. In some experiments, PKH2-PCL green (0.25 mM, 0.5 mL) was injected I.P at 48 h and peritoneal cells were recovered 4 h later, immunostained for F4/80 and CD11b as above and analyzed for fluorescence intensity of different macrophage populations. In relevant experiments, vehicle, RvD1, RvE1 (100 ng/mouse each), or Dex (25 mg/mouse) were introduced to the peritoneum 48 h after peritonitis initiation, and the exudates were recovered after 66 h and analyzed as before.
(94) Western Blot Analysis for CD11b.sup.high and CD11b.sup.low Macrophages
(95) Protein extracts of sorted populations (>95% purity) of CD11b.sup.high and CD11b.sup.low macrophages were run using 10% SDS-PAGE (50 μg/lane), transferred to nitrocellulose membranes, and immunoblotted with either goat anti-mouse CD11b (Santa-Cruz Biotechnology), rabbit anti-mouse iNOS (Abcam), goat anti-mouse arginase-1 (Abcam), rabbit anti-mouse COX-2 (Cayman Chemicals), sheep anti-mouse 12/15-LO (Cayman Chemicals), goat anti-mouse MMP-9 (R&D Systems), goat anti-mouse β-actin (Santa Cruz Biotechnology) or goat anti-mouse tubulin (Santa Cruz Biotechnology). Then, the membranes were washed and incubated with the appropriate HRP-conjugated secondary antibody. The blots were washed and developed using EZ-ECL (Biological Industries).
(96) Macrophage Transfer
(97) Macrophages were isolated from peritoneal exudates 48 h post-peritonitis initiation, stained with CFSE (1 mM), and injected into the peritoneum of mice that underwent peritonitis for 4 h. After an additional 18 h, cells from peritoneal exudates, inguinal lymph nodes (LN), and spleen were recovered from the recipient mice, immunostained as above, and the percentage of CD11b.sup.high and CD11b.sup.low macrophages in each site was determined.
(98) Confocal Microscopy
(99) Sorted CD11b.sup.high and CD11b.sup.low macrophages were isolated and loaded with 50 nm LysoTracker Red DND 99 dye (Molecular Probes) for 2 h at 37° C. in RPMI. Cells were then fixed with 2% paraformaldehyde at room temperature and stained with Hoechst (Molecular Probes) and FITC-conjugated anti-mouse Ly-6G. Mounted slides were kept in the dark at 4° C. until analyzed by confocal microscopy. Confocal images were acquired using Z-sections of 1 μm thickness. The images were processed with Zeiss LSM Image Browser software.
(100) Apoptotic PMN (Polymorphonuclear) Engulfment Enumeration
(101) Exudate cells or sorted CD11b.sup.high and CD11b.sup.low macrophages were stained with Hoechst, and enumerated under a fluorescent microscope (Zeiss). Two areas of two cover slips, each containing at least 50 (overall 200) macrophages were analyzed, and the average number of PMN engulfed per macrophage as well as the number of macrophages with cutoff numbers of engulfed PMN, were calculated. In sorted cells, F4/80.sup.+, Ly-6G.sup.+ entities (identified as macrophages that are attached to but did not fully engulf a PMN by forward versus side scatter analysis) were excluded from the samples to avoid counting of attached PMN.
(102) TLR-Mediated Responsiveness Ex Vivo
(103) Exudate macrophages were sorted or separated using PE selection magnetic beads (StemCell Technologies) and incubated (1×10.sup.6 cells in 0.5 mL of culture media) with LPS (0-1000 ng/mL), poly (I:C) (4 μg/mL), or CpG-ODN (1 μM). After 16 h, the supernatants were collected and their TNF-α, IL-β, IL-10, TGFβ, CCL2, CCL3, and CCL5 contents were determined by standard ELISA.
(104) Regulation of Macrophage Phenotype by Apoptotic Cells Ex Vivo
(105) Jurkat cells (T lymphocyte cell line) were treated with 1 mM staurosporine (4 h, Sigma) to induce apoptosis and washed. Then, peritoneal macrophages or sorted subpopulations thereof were incubated in the presence or absence of apoptotic Jurkat cells (1:5 macrophage to apoptotic cell ratio). At the beginning of the incubation and after 20 h, macrophages were immunostained for CD11b and analyzed by FACS analysis. Alternatively, protein extracts were prepared from the macrophages after the incubation period and run by SDS-PAGE followed by western blot analysis for CD11b, arginase-1, 12/15-LO, actin, and tubulin, as above.
(106) Cell Line Cultures
(107) Mouse mammary cancer cells D2.0R (obtained from Prof. Ann F. Chambers, described in Morris et al., Clinical & Experimental Metastasis 1993, 11(1):103-112), Mouse Embryonic Fibroblast (MEF) cell line (obtained from Dr. Sarit Larisch, Haifa University, Haifa, Israel) were maintained in DMEM high glucose (GIBCO), 10% fetal bovine serum (FBS), and 1% penicillin-streptomycin at 37° C., 5% CO.sub.2 incubator. Jurkat T cells (obtained from Prof. Debbie Yablonski, Technion, Israel) were maintained in RPMI-1640 (GIBCO) high glucose, 10% fetal bovine serum (FBS), and 1% penicillin-streptomycin at 37° C., 5% CO2 incubator.
(108) Fibroblasts differentiation to myofibroblasts was promoted as follows: Mouse embryonic fibroblasts (MEFs) were culture in DMEM 10% FBS medium in 6 well plates. The next day the cells were overlaid with RPMI containing 1% penicillin-streptomycin media for overnight incubation. Thereafter the cells were treated with RPMI 10% FBS medium containing 1 ng/ml TGFβ1 for 48-72 hours (PeproTech, Israel).
(109) Animals
(110) 7-8 weeks old male C57BL mice were purchased from Harlan Biotech Israel and maintained under special pathogen-free conditions in the animal facility at the Gutwirth Science Park in the Technion (Israel Institute of Technology, Haifa).
(111) Apoptotic Cells Preparation
(112) Apoptosis was initiated in Jurkat T cells by treating the cells with staurosporine (1 μg/ml; Sigma-Aldrich) for 4 hours. Then the cells were washed twice with PBS, re-suspended in RPMI 10% FBS medium and added to the plated macrophages.
(113) Ex-Vivo Generation of Pro-Resolving CD11b.sup.low Macrophages
(114) The isolated macrophages (Mφ) were incubated with apoptotic Jurkat T cells (AC). 5.Math.10.sup.6 cells were used at the following Mφ to AC ratios of: 1:1, 1:2 and 1:5, respectively. After 8 hours of incubation the cells were washed with PBS and overlaid with fresh RPMI 10% FBS medium for additional 12 hours of incubation. Next, conditioned medium was collected and the macrophages were further characterized for their conversion to CD11b.sup.low phenotype by determining their surface expression of CD11b by FACS analysis.
(115) FACS Analysis
(116) Determining surface expression of CD11b was carried out as follows: Exudates were blocked with FcR blocker (anti-CD16/CD32; Biolegend) mAb (0.5 μg/0.5×10.sup.6 cells), and co-stained with PE-conjugated anti mouse F4/80 (Cat #12216) (0.5 μg/0.5×10.sup.6 cells) and PerCP-conjugated anti-mouse CD11b (Cat #101230) (0.5 μg/0.5×10.sup.6 cells) for 20 min at 4° C. Then, cells were washed with FACS Buffer (1% BSA in PBS) and analyzed by FACSCanto ii (BD Biosciences) and FACSDiva software.
(117) Western Blot Analysis for MEFs
(118) MEFs were lysed in WCE (whole-cell extract) buffer [25 mM Hepes, pH 7.7, 0.3M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton X-100, 100 μg/ml PMSF and protease inhibitor cocktail (Rosche, 1:100 dilution)]. The proteins were separated by SDS-PAGE (8-10%) followed by transfer on to a nitrocellulose membrane. The membrane was blocked with 5% (w/v) non-fat dried skimmed milk powder in PBS supplemented with 0.05% Tween20 (PBS-T) for 1 hour at room temperature (R.T). Membrane was then probed either with mouse anti α-SMA (Cat #ab7817; Abcam), or with rabbit anti-mouse GAPDH (Cat #sc25778; Santa Cruz Biotechnology) at 4° C. overnight.
(119) Next, the membrane was incubated with the appropriate HRP-conjugated secondary antibody, for 1 hour at R.T. and washed 15 min×3 with PBS-T, WesternBright ECL (Advansta) was added to the membrane for 30 seconds and analyzed using ImageQuant LAS-4000 analyzer (GE Healthcare Life Sciences) & “ImageQuant LAS-4000” software (GE Healthcare Life Sciences). Densitometry analysis was performed using ImageQuant total lab 7 (GE Healthcare Life Sciences), an image analysis software.
(120) Three-Dimensional Cell Cultures
(121) D2.0R stably expressing Green Fluorescence protein (D2.0R-GFP cells) and MEF cells were harvested from their growth plates using 0.25% trypsin EDTA. Collected cells were cultured in Cultrex® growth factor reduced Basement Membrane Extract (BME: Trevigen, Inc) as follows: An 8-well chamber glass slide system (Lab-TEK® II, Naperville, Ill.) was coated with 50 μl Cultrex® (Basement membrane Extract; BME) (Barkan et al., 2010a) (protein concentration between 15 mg/ml; thickness 1-2 mm). 5×10.sup.3 cells/well of D2.0R-GFP cells, and 6×10.sup.4 MEF cells were re-suspended in DMEM low glucose supplemented with 2% FBS and 2% Cultrex® and either cultured separately or co-cultured on the coated slides. Slides were incubated at 37° C., 5% CO.sub.2 incubator. Cell morphology was monitored by light microscopy.
(122) Immunofluorescence Staining in Cell Culture
(123) Cells cultured in 8-well chamber glass slides in 2 dimensional culture or in 3 dimensional culture, were fixed and treated for 5 minutes with 4% Paraformaldehyde (PFA) containing 5% sucrose and 0.1% Triton X-100, and re-fixed for an additional 25 minutes with cold acetone for 10 minutes. The cells were washed for 10 minutes with PBS and an additional 15 minutes with PBS containing 0.05% Tween 20 (Sigma). Next, fixed cells were blocked with IF buffer (130 mM NaCl, 7 mM Na2HPO4, 3.5 mM NaH2PO4 , 7.7 mM NaN3, 0.1% BSA, 0.2% Triton X-100, 0.05% Tween 20) contain 10% donkey serum for 1 hour and incubated overnight at 4° C. with goat anti type I collagen (1:100) (Cat #1310-01; SouthernBiotech) together with Alexa Fluor® 488 phalloidin (1:40; Molecular Probes). The cells were washed three times with PBS for 15 minutes each, and incubated for 1 hour with donkey anti goat conjugated to Alexa Fluor® 649, (Invitrogen) at R.T. Next, the cells were washed as mentioned above and mounted with VECTASHIELD mounting medium with 4′,6-diamidino-2-phenylindole (DAPI). The slides were imaged using a Nikon A1-R confocal laser scanning microscope (Haifa University, Haifa, Israel).
(124) Apoptosis Detection
(125) MEF cell line were cultured as described above in 8 well chamber glass slides, fixed with 4% PFA containing 5% sucrose and incubated for 1 hour with a mixture of TUNEL reaction mix according to the manufacturer's protocol (In Situ Cell death Detection Kit; TMR Red) covered with aluminum foil and placed in the 37° C., 5% CO.sub.2 incubator for 1 hour. Next, the slides were washed three times with PBS for 15 minutes each, and mounted with VECTASHIELD mounting medium with DAPI. The slides were imaged using a Nikon A1-R confocal laser scanning microscope (University of Haifa, Haifa, Israel).
(126) Proliferation Assay
(127) MEF cells were cultured in 96 wells plate (1.5×10.sup.3 Cells/well). At indicated time points the CellTiter 96 AqueousOne Solution cell proliferation assay kit (Promega) was added to the wells for 2 hours to measure cell proliferation according the manufacturer's instructions. The absorbance was recorded at 490 nm.
(128) 2Images Analysis
(129) 3 images were captured from each well. Each captured frame was analyzed using NIS-Elements AR software to measure in the defined area the number of cells with positive DAPI staining, co-staining for DAPI and TUNEL (selected cells were larger than 8 μm), or Col-I expression by measuring sum intensity of area stained for Col-I per captured field.
(130) 3D Images Analysis
(131) Confocal images were acquired using Z-sections of 1 □m thickness. Three images comprised of 15 Z-stacks images were captured from each well. Each Z-stack was analyzed using NIS-Elements AR software to measure sum intensity of area stained for Col-I.
(132) Statistical Analyses
(133) Ex vivo and in vivo experiments were performed at least three times with at least four replicates. Results were analyzed by one-way analysis of variance (for multiple groups) or Student's t-test (for comparison between two groups, used for proliferation assays, TUNEL assay, densitometry for W.B membranes and quantification of Col-I) with statistical significance defined as P≦0.05 (*), P≦0.001 (**), or P≦0.0001 (***).
Example 1
Characterization of Protein Expression Profile and Differentiation Markers of CD11blow and CD11bhigh Macrophages
(134) Macrophages positive for the macrophage differentiation marker F4/80 obtained from mouse peritoneal exudates following induction of peritonitis were characterized and sorted according to their CD11b expression as detailed above. It was found that at 66 h after peritonitis initiation, 70% of the exudate cells were macrophages, of which 17% expressed low levels of CD11b (“CD11b.sup.low”). As can be seen in
(135) Analysis of some proteins that are functionally relevant to inflammation and well-characterized by their expression in classically (M1)- and alternatively (M2)-activated macrophages was performed in CD11b.sup.high and CD11b.sup.low macrophages. The analysis has shown (
(136) Further analysis have shown that the macrophage differentiation marker F4/80was expressed to a higher extent on CD11b.sup.high macrophages, further indicating that these cells possess different properties in comparison to CD11b.sup.low macrophages (data not shown).
(137) Further analysis of surface receptor expression revealed reduced expression of CD206 and CD163 (both M2 markers) on CD11b.sup.low macrophages, in comparison to their CD11b.sup.high counterparts (19- and 17-fold difference, respectively; N=3, data not shown).
(138) Thus, CD11b.sup.high and CD11b.sup.low macrophages display different expression profiles of functional proteins and differentiation markers.
Example 2
Engulfment of Apoptotic Polymorphonuclear Cells (PMN) by CD11blow Macrophages
(139) To examine whether CD11b.sup.low macrophages differ in their efferocytosis capacity from CD11b.sup.high, sorted CD11b.sup.high and CD11b.sup.low macrophages were stained with Hoechst and LysoTracker, analyzed by confocal microscopy, and photographed (not shown). Similar preparations were enumerated for apoptotic PMN uptake, and analyzed according to average neutrophils engulfed per macrophage (N/M), and percentage of cells reaching engulfment threshold or engulfing an indicated number of apoptotic PMN. The results are shown in
(140) The analysis has shown that CD11b.sup.low macrophages engulfed significantly more PMN on average than CD11b.sup.high macrophages (12.2±0.2 N/M and 2.2±0.2 N/M, respectively, see
Example 3
Responsiveness of CD11bhigh Macrophages to TLR (Toll-Like Receptors) Ligands
(141) Sorted macrophages were activated with LPS, and the secretion levels of TNF-α, IL-β, IL-10, and TGFβ by CD11b.sup.high and CD11b.sup.low macrophages were determined. The results are presented in
(142) In addition, CD11b.sup.low and CD11b.sup.high macrophages were stimulated with the TLR3 and TLR9 ligands poly (I:C) and CpG-oligodeoxynucleotides (CpG-ODN), respectively, and the secretion of TNF-α and IL-β was determined (
Example 4
The Phagocytic Capacity of CD11blow and CD11bhigh Macrophages
(143) To determine whether CD11b.sup.low and CD11b.sup.high macrophages differ in their ability to phagocytose external particles, the phagocyte-specific dye PKH2-PCL green was injected intraperitoneally (i.p.) to mice undergoing peritonitis for 48 and 4 h later the peritoneal cells were recovered, immunostained, and analyzed for PKH2-PCL acquisition. The results are shown in
(144) Thus, CD11b.sup.low macrophages may be considered “satiated”, meaning that they lost their phagocytic potential upon meeting the apoptotic PMN engulfment threshold and reducing their CD11b expression.
Example 5
Migration of CD11blow Macrophages to Lymphoid Organs
(145) To determine whether CD11b.sup.low macrophages are prone to depart resolving inflammation sites and emigrate to lymphoid organs, the relative distribution of CD11b.sup.high and CD11b.sup.low macrophages 66 h post-peritonitis initiation was determined at the peritoneum, inguinal LN, and spleen. The results (
Example 6
Ex-Vivo Generation of Macrophages Expressing Low Levels of CD11b
(146) Sorted CD11b.sup.high and CD11b.sup.low macrophages were incubated with or without apoptotic Jurkat cells and the changes in surface expression of CD11b were determined. The results (
(147) The reduction in macrophage CD11b expression ex vivo appears to be specific for interaction with apoptotic cells, and could not be achieved by treatment with other phagocytic targets, prototypic-activating bacterial moieties, or pro-resolving cytokines, and is not due to the cell type of the apoptotic cells.
(148) To determine whether macrophage interaction with apoptotic cells also triggers the major differences in protein expression distinguishing CD11b.sup.high and CD11b.sup.low macrophages that are shown in
(149) Ex vivo exposure of macrophages to senescent neutrophils, but not to latex beads (LB) or IgG-opsonized LB, resulted in a significant reduction in CD11b and arginase-1 expression, whereas 12/15-LO expression was increased in this setting by all phagocytic targets. These results indicate that interaction with apoptotic cells is sufficient to drive the conversion of CD11b.sup.high to CD11b.sup.low macrophages.
Example 7
RvD1, RvE1, and Dex Reduce the PMN Engulfment Threshold Required for Macrophage Immune-Silencing
(150) Resolvins are resolution-phase-generated mediators derived from Ω-3 polyunsaturated fatty acids; they were found to promote resolution by acting on PMN and macrophages. Similar properties were attributed to glucocorticoids, such as dexamethasone (Dex), that inhibit leukocyte infiltration to inflammation sites and promote the clearance of apoptotic PMN by macrophages. To determine whether pro-resolving mediators regulate emergence of CD11b.sup.low macrophages and thereby promote resolution, RvD1, RvE1, or Dex were introduced into peritonitis-affected mice, and the recovered leukocytes were collected and analyzed for macrophage and neutrophil numbers, macrophage CD11b expression, engulfment of PMN, and responsiveness to LPS. The results are presented in
(151) To validate the improvement in immune-silencing of macrophages that followed treatment with RvD1, RvE1 and Dex, macrophages were activated with LPS, and cytokine secretion was determined. The results indicate that RvD1 and RvE1, and, to a lesser extent, Dex, inhibited the secretion of TNFα from unstimulated and LPS-stimulated macrophages. A similar response was observed with RvD1, RvE1 and Dex when IL-1β secretion from LPS-stimulated macrophages was determined. The secretion of IL-10, a pro-resolving cytokine generated following the ingestion of apoptotic cells, was up-regulated by each of the pro-resolving mediators, in unstimulated and LPS-stimulated macrophages. Thus, treatment with RvD1, RvE1, and Dex, promoted macrophage immune-silencing, as well as the secretion of pro-resolving cytokines from these cells.
(152)
Example 8
Ex Vivo Treatment with Pro-Resolving Lipid Mediators Promotes Macrophage Switch to the CD1blow Phenotype
(153) Macrophages were recovered from peritoneal exudates 72 hrs post peritonitis initiation and incubated overnight with either RPMI 10% FBS+0.05% ethanol, the resolvins RvD1 or RvD2, cell death protein PD1 or lipoxins LXB.sub.4, or 15-epi-LXA.sub.4, (all at 50 nM), apoptotic cells (M/N ratio of 1:5), or Dex (25 μg/ml). After 20 hours, the cells were stained for CD11b and analyzed by flow cytometry. As can be seen from
Example 9
Ex-Vivo Generation of Secreted Factors of Pro-Resolving CD11blow Macrophages
(154) Conditioned media of enriched CD11b.sup.high macrophages (CM-Mck) and of ex-vivo generated pro-resolving CD11b.sup.low macrophages (CM-Mres) was collected in order to test their impact on the formation of a fibrotic ECM by myofibroblasts and the transition from tumor dormancy to metastatic growth as detailed below. To this end peritonitis was induced and 66 hours later peritoneal exudates were collected and the percentage of macrophages was determined in peritoneal exudates, based on their size and granularity (
Example 10
CM-Mres Prevents Fibroblasts Differentiation to Myofibroblasts in 2 Dimensional Cultures
(155) We next determined whether conditioned media recovered during the conversion of CD11b.sup.high macrophages to CD11b.sup.low macrophages (CM-Mres) (as described in Example 9) was able to inhibit the differentiation of fibroblasts to myofibroblasts. In order to address this question we tested proliferation of fibroblasts, their expression of α-SMA and expression and deposition of Type I collagen (Col-I) upon treatment with CM-Mres.
(156) Initially, we carried out a qualitative experiment to determine the growth of fibroblasts. To this end mouse embryonic fibroblasts (MEFs) were induced to differentiate to myofibroblasts by treating the cells with 1 ng/ml TGFβ1 for 72 hours. To test the impact of the conditioned media on the activation of MEFs we carried out the following: 1 hour prior to adding TGFβ1, the MEFs were either untreated or treated with either condition media of CD11b.sup.high-enriched macrophages (CM-Mφ)) or with CM-Mres for 72 hours. Our results demonstrate that fewer MEFs were present in plates treated with CM-Mres and TGFβ1, compared to untreated MEF or to MEF treated with either CM-Mφ and TGFβ1 or with TGFβ1 alone (
Example 11
MEFs Treated with CM-Mres are Cell cycle Arrested
(157) We further studied whether reduction in the number of MEFs that were treated with TGFβ1+CM-Mres was due to inhibition of proliferation. To this end condition media from either cultured residual AC (CM-AC), CM-Mφ or CM-Mres was overlaid on starved MEFs cultured on 96 well plates 1 hour prior to TGFβ1 treatment. Proliferation of the cells was monitored 24, 48 and 72 hours after addition of TGFβ1.
(158) Our results demonstrate that TGFβ1 promotes the proliferation of MEF as expected in a time dependent manner. Furthermore CM-Mφ did not significantly affect the proliferation of MEF that were treated with TGFβ1, however the CM-Mres inhibited significantly the TGFβ1 induced proliferation of MEFs cells (
(159) Next we explored whether the inhibition of MEF proliferation by the CM-Mres was due to cell cycle arrest or increase in apoptosis of MEF. Therefore, we tested apoptosis of the MEFs at 48 hours. At this time point significant changes in the proliferation of the cells was already observed as shown in
Example 12
CM-Mres Inhibit α-SMA expression by MEF Treated with TGFβ1
(160) We further explored the effect of CM-Mres on differentiation of MEF to myofibroblasts by testing the expression of α-SMA. To this end, we either undifferentiated or differentiated MEF in the presence of CM-Mres, CM-Mφ, or CM-AC 1 hour before adding TGFβ1, for 72 hours. Protein lysates were collected and α-SMA levels were determined by western blot analysis. CM-Mres inhibited significantly the expression of α-SMA in MEF treated with TGFβ1 compared to the expression levels in MEF treated with TGFβ1+CM-Mφ (
Example 13
CM-Mres Inhibit Type I Collagent Expression by MEF Treated with TGFβ1
(161) Type I Collagen (Col-I) is expressed in differentiated fibroblasts. Therefore, we tested whether CM-Mres will inhibit Col-I expression in TGFβ1-treated MEF. To this end MEF were cultured on 8 chamber glass slides and were either untreated or treated with TGFβ1 in the presence of either CM-Mres, CM-Mφ or CM-AC. We determined Col-I expression by immunofluorescence staining and F-actin organization by phalloidin staining (data not shown). Our results demonstrated that CM-Mres significantly inhibited Col-I expression of TGFβ1 treated MEF compared to untreated MEF and to TGFβ1 treated MEF that were treated with either CM-Mφ or CM-AC (
Example 14
CM-Mres Prevent Production of Col-I by Myofibroblast Cultured in 3D System
(162) A novel 3D BME system to model tumor dormancy and outgrowth was described recently in Barkan et al., 2011. Furthermore, supplementing the 3D BME system with Col-I was shown previously to induce the transition of dormant D2.0R cells from quiescence to proliferative growth. Therefore, we wanted to explore whether MEF cultured in the 3D BME system will successfully differentiate to myofibroblasts, express Col-I and thus will induce dormant D2.0R cells outgrowth. If successful, we will test whether we can prevent the D2.0R cells outbreak by using CM-Mres. To this end MEF cells were cultured in the 3D BME system and were either untreated or treated with CM-Mφ, CM-AC or CM-Mres for 7days. Col-I expression was determined by immunofluorescence staining. Our results demonstrate that MEFs cultured in the 3D BME system differentiated to myofibroblasts given they expressed Col-I (
Example 15
Conditioned Media of Ex-Vivo Generated CD11blow Macrophages (CM-Mres) Inhibit Proliferation and Induce Cell Death of D2A1 Dormant Tumor Cells
(163) Peritoneal mouse macrophages were recovered 66 hours post peritonitis initiation and incubated either with no cells, or in the presence of apoptotic (AC) or live (LC) Jurkat cells. The unbound apoptotic cells were then washed and the macrophages were recovered and immunoassayed for CD11b expression on their surface. Expression of CD11b was determined by FACS analysis. As can be seen in
(164) The conditioned media were overlaid on D2A1 cells cultured in the 3D BME system on day 2 when cells are dormant, and on day 4, prior to their transition from quiescence to proliferation. Proliferation of the D2A1 cells was determined by using the Cell Titer 96 Aqueous One Solution cell proliferation assay kit (Protégé; Madison, Wis.) as described by Barkan et al. 2008.
(165)
(166) The results demonstrate that conditioned media obtained from ex-vivo generated macrophages expressing low levels of CD11b (CD11b.sup.low) induced cell death of outbreaking D2A1 cells during their transition from dormancy to proliferation in the 3D system.
(167)
(168) The results indicate that soluble factors secreted by the CD11b.sup.low macrophages, which are present in the conditioned media, induce cell death of dormant D2A1 cells. Thus, dormant disseminated tumor cells may be eradicated by natural soluble factors produced by immune cells participating in physiological healing processes.
Example 16
CM-Mres Prevent Metastatic Outbreak of Dormant Tumor Cells Co-Cultured with Myofibroblasts
(169) Our findings demonstrated that culturing MEFs in the 3D BME system promoted their differentiation and the expression of Col-I and this differentiation was inhibited by treatment with CM-Mres. D2.0R cells cultured in the 3D BME system are dormant and supplementing the BME with Col-I was shown previously to induce their outbreak (Barkan et al., 2010a). Hence, based on our recent and previous results we next tested whether 1) co-culture of dormant D2.0R cells with MEF in the 3D BME system will induce their emergence from tumor dormancy to proliferative growth and 2) whether treatment with CM-Mres will inhibit Col-I expression and will prevent D2.0R cells outbreak. To this end we co-cultured D2.0R cells stably expressing green fluorescent protein (D2.0R-GFP) with MEF for 7 days. Our results showed that D2.0R-GFP cells cultured in the BME system remain dormant as expected, whereas co-culture of D2.0R-GFP cells with MEF in the 3D BME system, promoted their outbreak (dramatic increase in cell number) and Col-I expression was evident (data now shown). Similarly D2.0R-GFP cells emerged from their dormant state in the presence of MEF treated with CM-Mφ. However, treatment of the co-culture with CM-Mres prevented Col-I expression by the differentiated MEF and lower number of D2.0R-GFP were evident compared to untreated co-culture or co-culture treated with CM-Mφ.
Example 17
In Vivo Treatment of Dormant and Outbreaking Tumor Cells with CM-Mres
(170) Conditioned media of ex-vivo generated CD11b.sup.low (CM-Mres) and control CD11b.sup.high macrophages (CM-Mφ) (as described in Example 9) is assayed for their impact on the metastatic outbreak in vivo, using tumor-inoculated mice. Experimental metastasis assay in athymic nude mice are carried out in female athymic nude mice (n=30) injected via tail vein with D2A1 cells stably expressing GFP (D2A1-GFP cells) to allow tracking by live video microscopy as described previously as described in Barkan et al. 2008 and 2010a. Prior to the outbreak of dormant D2A1-GFP cells (5 days post D2A1-GFP injection) 15 of the recipient mice are treated (50-100 μl, intranasal or via tail vain injection) with CM-Mφ. (control group), whereas the rest of the recipient mice (n32 15) are treated with CM-Mres (treated group). The control and treated groups are divided to 3 even groups (n=5; control groups A/B/C and treated groups A/B/C). Control and treated group B and C receive additional treatments at days 8 and 11 of either CM-Mφ or CM-Mres, respectively. Lungs from all groups (and untreated mice; n=5) are harvested 2 weeks post injection of D2A1-GFP cells, and tumor cells are analyzed for their dormant or metastatic growth using live video microscopy as described previously in Barkan et al. 2008 and 2010a. Imaged lungs are frozen in optimal cutting temperature (OCT) compound for determination of extent of fibrosis at the metastatic site by immunofluorescence staining for Col-I and macrophages (F4/80 staining) of frozen sections prepared from the harvested lungs.
(171) Metastatic outbreak in the control groups treated with CM-Mφ, with possible enhancement of the extent of metastasis compared to untreated mice may be expected, whereas in the CM-Mres-treated group the number of lesions will decrease and the majority of the lesions are expected to be dormant with inhibition of a fibrotic stroma at the metastatic site (depicted by low expression of Col-I and clearance of macrophages).
(172) The following experiments are repeated with highly metastatic human breast cancer cell line such as MDA-MB-231 cells. The mice are treated as above but at two weeks when metastatic lesions are already established.
(173) In the CM-Mres-treated group, the number of lesions is expected to decrease and the majority of the lesions are expected to be dormant with inhibition of a fibrotic stroma at the metastatic site (depicted by low expression of Col-I and clearance of macrophages).
Example 18
Treatment of Tumor Metastasis by Administering Mres Macrophages
(174) Ex-vivo generated peritoneal/lung pro-resolving CD11b.sup.low macrophages (Mres macrophages) are prepared as described in Example 9. Initially, a pilot experiment is conducted to determine the transfer regimen of the ex-vivo generated Mres macrophages required to promote inhibition of the metastatic outbreak in the lungs. The transfer is carried out by intranasal administration. To this end, experimental metastasis assays are carried out on recipient female athymic mice (n=30) that are injected via tail vein with D2A1-GFP cells in order to analyze later on their dormant and metastatic outbreak by live video microscopy as described previously in Barkan et al. 2008 and 2010a. Prior to the outbreak of dormant D2A1-GFP cells (5 days post D2A1-GFP injection), 15 of the recipient mice are transferred with isolated and sorted CD11b.sup.high macrophages obtained from 45 donor mice with peritonitis (control group), whereas the rest of the recipient mice (n=15 mice) are transferred with an equal number of sorted ex-vivo generated Mres macrophages (treated group). The control and treated groups are divided to 3 even groups: Control group A/B/C (n=5 mice per each group) and treated group A/B/C (n=5 mice per each group). Control and treated group B receive an additional transfer 3 days later of either freshly prepared pro-resolving CD11b.sup.high or ex-vivo generated Mres macrophages (as described above), respectively, whereas control and treated group C receive two additional transfers, at 3 day intervals, with either freshly prepared CD11b.sup.high or ex-vivo generated Mres macrophages, respectively. Lungs from all groups of mice are harvested 2 weeks post injection of D2A1-GFP cells, and tumor cells are analyzed for their dormant or metastatic growth using live video microscopy. Imaged lungs are frozen in OCT for determination of extent of fibrosis at the metastatic site by immunofluorescence staining for Col-I and macrophages (F4/80 staining) of frozen sections prepared from the harvested lungs.
(175) Metastatic outbreak in the control group transferred with CD11b.sup.high macrophages is expected, with possible enhancement of the extent of metastasis, whereas in the treated group the majority of the lesions are expected to be dormant. Once the transfer regimen needed to inhibit the metastatic outbreak of D2A1-GFP cells is established, the experiment is repeated with a larger cohort of mice transferred with ex-vivo-generated peritoneal/lung Mres macrophages, and proceed to further confirm the promotion of resolution of the metastatic microenvironment as detailed below.
REFERENCES
(176) Ariel A, Serhan C N: New Lives Given by Cell Death: Macrophage Differentiation Following Their Encounter with Apoptotic Leukocytes during the Resolution of Inflammation. Frontiers in Immunology 2012, 3:4.
(177) Barkan D, Kleinman H, Simmons J L, Asmussen H, Kamaraju A K, Hoenorhoff M J, Liu Z Y, Costes S V, Cho E H, Lockett S et al: Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Research 2008, 68(15):6241-6250.
(178) Barkan D, Green J E, Chambers A F: Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. European Journal of Cancer 2010, 46(7):1181-1188.
(179) Barkan D, El Touny L H, Michalowski A M, Smith J A, Chu I, Davis A S, Webster J D, Hoover S, Simpson R M, Gauldie J et al: Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Research 2010a, 70(14):5706-5716.
(180) Barkan D, Green J E: An in vitro system to study tumor dormancy and the switch to metastatic growth. Journal of Visualized Experiments: JoVE 2011(54).
(181) Hasebe T, Sasaki S, Imoto S, Mukai K, Yokose T, Ochiai A: Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Modern Pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2002, 15(5):502-516.
(182) Luo, Yi and Knudson, M. J., Mycobacterium bovis Bacillus Calmette-Guérin-Induced Macrophage Cytotoxicity against Bladder Cancer Cells, Clin Dev Immunol. 2010:357591
(183) Mantovani A. et al., 2004. The chemokines system in diverse forms of macrophage activation and polarization. Trends Immunol, 25, 677-86.
(184) Mantovani A et al., 2005 Macrophage polarization comes of age. Immunity, 23, 344-.
(185) Martinez et al., 2009. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol, 27, 451-83.
(186) Schif-Zuck S, Gross N, Assi S, Rostoker R, Serhan C N, Ariel A: Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. European Journal of Immunology 2011, 41(2):366-379.